Other

Cryolog S.a.

Cryolog

Alaya.bio Inc.

Ixaka France

Sa Cryolog

Renaud Vaillant

Cecile Bauche

Cécile Bauche

Frédéric Mourlane

Emeline Sarry

Anna Miodek

Pierre Peteuil

Olivier Louvet

Dominique Thuault

Philippe Bishop

An aptamer-based switch technology is provided that enhances control of the use of chimeric antigen receptor (CAR)-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule containing a target-binding aptamer bound through a linker to a CAR-binding aptamer. A system containing a CAR and a corresponding aptameric bridge provides an immunotherapy platform that: (i) can be targeted to any desired antigen by choosing the target-binding aptamer of the bridge. (ii) can be redirected from one target to another by changing the target-binding aptamer: (iii) can be dosed according to the changing needs of an individual patient overtime by altering the administration protocol for the bridge: (iv) can be switched on or off quickly or gradually: (v) can be used as a companion diagnostic for a specific CAR therapy: (vi) can be integrated with either in vivo or ex vivo CAR expression: (vii) is non-immunogenic; and (viii) has low production costs.

Aptamer-based CAR T-cell switch

Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses and innate immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens, a combination of adjuvants, and optionally may encode one or more soluble and secreted checkpoint inhibitor molecules. The adjuvants include latent membrane protein 1 (LMP1) from Epstein Barr virus and a fusion protein including LMP1 with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.

Viral vector constructs for expression of genetic adjuvants activating the CD40 and STING pathways

Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens and an adjuvant, and optionally may encode one or more soluble checkpoint inhibitor molecules. The adjuvant is a fusion protein including latent membrane protein 1 (LMP1) from Epstein Barr virus with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.

Viral vector constructs for expression of genetic adjuvants activating the STING pathway

A process for manufacturing an individual packaging for a liquid or solid product includes uninterruptedly unwinding a lower film while simultaneously unwinding an upper film with regard to the lower film. The process further includes continuously dispensing, between the two films, the product which is to be packaged and simultaneously forming and sealing the contour of each packaging by ultrasonic welding. This welding is carried out so that the ultrasound ejects the product from the zones being welded.

Method and means for the high-speed manufacturing of individual packaging for a liquid or solid product

A method and device for determining whether a product is in condition to be used or consumed, this product being intended to be preserved under temperature conditions and for a period of time which limit its degradation includes an indicator combined with the product, to provide a signal indicating that the product can be used or consumed, and then, after the expiration of a preservation period of time, a signal indicating a change in the condition of possible use or consumption of the product. The period of time depends on the preservation conditions of the product. The indicator provides information enabling the product to be used or consumed for a longer period of time if the product has been preserved under conditions better than recommended conditions or for a shorter period of time if the product has been preserved under conditions worse than recommended conditions.

Method and device for determining if a product is in condition for use or consumption

The invention pertains to a method, a system and a component for systematically and automatically controlling a product, whose preservation in a distribution circuit depends on temperature, in particular a product subjected to a cold chain. The method includes: affixing, on the product, a marker including elements, in particular the bars of a bar code, intended to be identified by automatic processing units, fixing a component on the product. The component includes at least one part including a mask intended for masking the elements of the marker, at least temporarily, without modifying them, when (i) the temperature of the product exceeds a specific temperature threshold or (ii) when the preservation conditions differ from a specific reference level, in particular characterized by the exceeding of a specific temperature threshold for a longer duration than a specific duration or by the exceeding of a specific preservation duration.

Growing community of inventors

Gentilly, France

Renaud Vaillant